March 4, 2008

Skinvisible Announces Release of Independent Analyst Report

Las Vegas, Nevada - March 4, 2008 - Skinvisible, Inc. (OTC Bulletin Board: SKVI / www.skinvisible.com), a R&D pharmaceutical company that develops enhanced dermatology products and improves their life cycle management with the Company's patented polymer delivery system Invisicare®, announces the release of an independent analyst report by Fundamental Research Corp.

The report by Fundamental Research Corp.'s analyst Brian Tang, is available for review at skinvisible.com

Fundamental Research Corp., an independent research company, was provided compensation in connection with the report. Further information is located within the report.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a dermatology research-and-development company that licenses its proprietary formulations made with Invisicare as well as enhances existing products for pharmaceutical and cosmeceutical companies. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent. www.skinvisible.com

About Invisicare®

Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. Other key benefits include its ability to gradually release active ingredients which reduces skin irritation and increases efficacy, it is non-occlusive on the skin and new patents can be issued for products formulated with Invisicare. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries. www.invisicare.com